Valsartan-d<sub>9</sub>

Valsartan-d9

CAT N°: 25226
Price:

548.00 465.80

Valsartan-d9 is intended for use as an internal standard for the quantification of valsartan (Item No. 14178) by GC- or LC-MS. Valsartan is a nonpeptide antagonist of the angiotensin II type 1 (AT1) receptor (IC50 = 2.7 nM).{21001} It is 20,000-fold selective for AT1 over AT2 and, unlike some other AT receptor antagonists, does not alter peroxisome proliferator-activated receptor ? (PPAR?) activity in vitro.{20999} In vivo, valsartan (30 mg/kg) increases cardiac output and reduces left ventricular fibrosis in a model of heart failure with reduced ejection fraction in mice with streptozotocin-induced diabetes.{42153} Formulations containing valsartan have been used in the treatment of hypertension and heart failure.{13660,20999,12999}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-(1-oxopentyl-2,2,3,3,4,4,5,5,5-d9)-N-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-L-valine
  • Correlated keywords
    • CGP48933 NISIS valsartanin AT-1 2 deuterated deuterium CGP-48933 PPAR-?
  • Product Overview:
    Valsartan-d9 is intended for use as an internal standard for the quantification of valsartan (Item No. 14178) by GC- or LC-MS. Valsartan is a nonpeptide antagonist of the angiotensin II type 1 (AT1) receptor (IC50 = 2.7 nM).{21001} It is 20,000-fold selective for AT1 over AT2 and, unlike some other AT receptor antagonists, does not alter peroxisome proliferator-activated receptor ? (PPAR?) activity in vitro.{20999} In vivo, valsartan (30 mg/kg) increases cardiac output and reduces left ventricular fibrosis in a model of heart failure with reduced ejection fraction in mice with streptozotocin-induced diabetes.{42153} Formulations containing valsartan have been used in the treatment of hypertension and heart failure.{13660,20999,12999}

We also advise you